Department of Cardiology and Nephrology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kyoto 608-8566, Japan.
Clin J Am Soc Nephrol. 2011 Apr;6(4):718-23. doi: 10.2215/CJN.08310910. Epub 2011 Jan 21.
S100A12 is an endogenous receptor ligand for advanced glycation end products. Cardiovascular disease remains a major cause of morbidity and mortality in patients with chronic kidney disease. In this study, we report cross-sectional data on 550 hemodialysis patients and assess the relationship between plasma S100A12 level and cardiovascular disease.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A cross-sectional study of 550 maintenance hemodialysis patients was conducted. We investigated the past history of cardiovascular disease and quantified the plasma level of S100A12 protein in all participants.
Plasma S100A12 level was higher in hemodialysis patients with cardiovascular disease (n=197; 33.8 ± 28.1 ng/ml) than in those without it (n=353; 20.2 ± 16.1 ng/ml; P<0.001). In multivariate logistic regression analysis, the plasma S100A12 level (odds ratio [OR], 1.28; 95% confidence interval [CI], 1.13 to 1.44; P<0.001) was identified as an independent factor associated with the prevalence of cardiovascular disease. The other factors associated with the prevalence of cardiovascular diseases were the presence of diabetes mellitus (OR, 2.81; 95% CI, 1.79 to 4.41; P < 0.001) and high-sensitivity CRP level (OR, 1.02; 95% CI, 1.00 to 1.05; P=0.046). Furthermore, the plasma S100A12 level (OR, 1.30; 95% CI, 1.09 to 1.54; P=0.004) was significantly associated with cardiovascular disease even in hemodialysis patients without diabetes mellitus (n=348).
These results suggest that the plasma S100A12 protein level is strongly associated with the prevalence of cardiovascular disease in hemodialysis patients.
S100A12 是晚期糖基化终产物的内源性受体配体。心血管疾病仍然是慢性肾脏病患者发病率和死亡率的主要原因。在本研究中，我们报告了 550 名血液透析患者的横断面数据，并评估了血浆 S100A12 水平与心血管疾病之间的关系。
设计、地点、参与者和测量：对 550 名维持性血液透析患者进行了横断面研究。我们调查了心血管疾病的既往史，并对所有参与者的血浆 S100A12 蛋白水平进行了量化。
患有心血管疾病的血液透析患者（n=197；33.8±28.1ng/ml）的血浆 S100A12 水平高于无心血管疾病的患者（n=353；20.2±16.1ng/ml；P<0.001）。在多变量 logistic 回归分析中，血浆 S100A12 水平（比值比[OR]，1.28；95%置信区间[CI]，1.13 至 1.44；P<0.001）被确定为与心血管疾病患病率相关的独立因素。与心血管疾病患病率相关的其他因素包括糖尿病（OR，2.81；95%CI，1.79 至 4.41；P<0.001）和高敏 C 反应蛋白水平（OR，1.02；95%CI，1.00 至 1.05；P=0.046）。此外，即使在没有糖尿病的血液透析患者（n=348）中，血浆 S100A12 水平（OR，1.30；95%CI，1.09 至 1.54；P=0.004）与心血管疾病显著相关。
这些结果表明，血浆 S100A12 蛋白水平与血液透析患者心血管疾病的患病率密切相关。
